Core Insights - Oscar Health (OSCR) is a health insurance company primarily operating in the ACA marketplace across 18 states, focusing on individual health plans [1] Company Overview - Oscar Health specializes in providing health insurance plans to individuals, leveraging the ACA marketplace [1] Analyst Background - The analysis is conducted by an IMC qualified contributor with 5 years of experience in financial markets and over 2 years in primary investment research, focusing on smaller, under-covered companies for potential investment opportunities [1]

Core Insights - Oscar Health (OSCR) is a health insurance company primarily operating in the ACA marketplace across 18 states, focusing on individual health plans [1] Company Overview - Oscar Health specializes in providing health insurance plans, mainly targeting the Affordable Care Act (ACA) marketplace [1] - The company has been covered in previous analyses, indicating ongoing interest and monitoring of its performance [1] Analyst Background - The analysis is conducted by an IMC qualified contributor with 5 years of experience in financial markets and over 2 years in primary investment research [1] - The analyst adopts a bottom-up research approach, focusing on smaller, under-covered companies to identify mis-pricing and asymmetric investment opportunities [1]

We came across a bullish thesis on Oscar Health, Inc. on Investment Ideas by Antonio’s Substack by Antonio Linares. In this article, we will summarize the bulls’ thesis on OSCR. Oscar Health, Inc.'s share was trading at $17.97 as of November 28th. Oscar Health, Inc. operates as a healthcare technology company in the United States. OSCR is positioned to benefit from a structural shift in the U.S. healthcare system, as evidenced by a rising medical loss ratio (MLR) driven by higher average market morbidity ...

Core Insights - Longleaf Partners Small-Cap Fund reported a return of 2.03% in Q3 2025, underperforming compared to the Russell 3000's 8.18% and the Russell 2000's 12.39% [1] - Oscar Health, Inc. (NYSE:OSCR) experienced a one-month return of -2.97% and a 52-week decline of 7.45%, closing at $16.65 per share with a market capitalization of $4.794 billion on December 1, 2025 [2][3] Fund Performance - The Longleaf Partners Small-Cap Fund's performance in Q3 2025 was significantly lower than major indices, indicating challenges in stock selection or market conditions [1] Oscar Health, Inc. Analysis - Oscar Health transitioned from being a contributor to a detractor in the fund's performance, with claims losses in the healthcare sector being worse than expected [3] - The fund sold its remaining position in Oscar Health as the price-to-value gap closed, marking the investment as successful despite the volatility [3] - Oscar Health reported approximately $3 billion in revenue for Q3 2025, reflecting a 23% year-over-year increase [4] Hedge Fund Interest - Oscar Health was held by 40 hedge fund portfolios at the end of Q3 2025, a decrease from 43 in the previous quarter, indicating a decline in popularity among hedge funds [4] Investment Outlook - While Oscar Health shows potential, the fund suggests that certain AI stocks may offer better upside potential with less downside risk [4]

Core Viewpoint - Investors are currently concerned about the healthcare industry, particularly health insurers like UnitedHealth Group, which have seen significant stock declines due to rising claims and medical costs. However, Oscar Health is positioned to return to profitability by 2026 despite current challenges [1][2]. Company Overview - Oscar Health is an emerging health insurer targeting the individual paying market, which has faced rising costs but is expected to benefit from long-term trends in the healthcare sector [2][4]. - The company has grown its customer base from 200,000 in 2019 to 2.1 million in the last year, leveraging a technology-driven approach to enhance customer experience [10]. Financial Performance - Oscar Health reported a quarterly operating loss of approximately $129 million due to increased medical loss ratios stemming from higher service usage [5]. - The company plans to increase health insurance plan prices by 28% in 2026 to address losses and aims to maintain $12 billion in premium revenue despite potential customer declines [8][12]. Market Dynamics - The expiration of COVID-19 related healthcare subsidies is expected to reduce the number of individuals purchasing insurance, impacting Oscar Health's customer base in the short term [6][7]. - Despite these challenges, the overall shift from employer-based to individual payers in the health insurance market presents a long-term growth opportunity for Oscar Health [9]. Investment Potential - Current market conditions suggest that investors are overly pessimistic about Oscar Health's future profitability, with a potential price-to-earnings ratio below 8 if the company achieves a 5% net income margin [11][13].

Core Insights - The Trump administration is considering extending tax credits for individuals purchasing coverage under the Affordable Care Act (ACA), which has led to a rise in health insurance company stocks [2][4] - Enhanced tax credits introduced by the Biden administration in 2021 have significantly increased ACA enrollment, surpassing 24 million Americans [3] - Wall Street analysts view a potential two-year extension of these tax credits as beneficial for health insurers and their customers, contrasting with expectations of no extension or a shorter one [4] Company Performance - Health insurance stocks have seen a positive trend, with companies like Oscar Health, Elevance Health, and Molina Healthcare reporting significant share price increases [7][8] - Oscar Health's shares rose over 8% to $18.16, marking a weekly increase of more than 26% [7] - Elevance Health's shares increased nearly 1% to $338.49, with a weekly gain of over $20, while Molina Healthcare shares rose more than 7% and UnitedHealth Group shares increased by 5% [8] Industry Context - The health insurance industry has faced challenges in 2023 due to rising medical claims, but recent developments regarding tax credits have created a favorable environment for managed care companies [6][5] - The ongoing open enrollment period presents an opportunity to protect millions of Americans from rising healthcare costs in 2026 [9]

Core Insights - Oscar Health shares experienced a significant increase following an upgrade from Piper Sandler analysts, who raised their rating to "overweight" and increased the price target from $13 to $25 [2][4]. Stock Performance - Oscar shares rose by 9% in late trading, reaching approximately $18.20, and have gained about 35% over the past week [2][8]. - Prior to this rally, Oscar shares had remained relatively unchanged for the year, but the recent gains have allowed them to outperform the S&P 500 year-to-date [9]. Analyst Insights - Piper Sandler is the only firm with a "buy" rating on Oscar among six analysts, with one "hold" and four "sell" ratings, and an average price target of $15 [2]. - Analysts believe that even if Affordable Care Act (ACA) subsidies expire at the end of the year, Oscar can still grow its market share and profitability due to its strategic product design and pricing for 2026 [5][8]. Policy Impact - The potential extension of ACA subsidies is expected to lower costs for millions of Americans and stabilize enrollment rates, which would benefit health care companies like Oscar [4]. - Analysts at Piper Sandler assert that Oscar is well-positioned to adapt to various policy scenarios, indicating confidence in the company's management and product strategy [6].

Core Insights - EFG International hosted its Investor Day 2025 in Zurich, showcasing an improving weather condition which adds a positive atmosphere to the event [1] - The management team, including CEO Giorgio Pradelli and CFO Dimitris Politis, is present to engage with investors and provide insights [1][2] Presentation Overview - The event includes a program with interesting presentations and insightful information aimed at investors [2] - A Q&A session is scheduled to follow the presentations, allowing for direct interaction between management and investors [2]

Company Upgrades - Amazon received an outperform rating from JPMorgan, highlighting that the recent dip in share price presents a buying opportunity, with shares approximately 10% off November highs [5] - Goldman Sachs also reiterated a buy rating on Amazon, emphasizing its strong positioning for the holiday season [5] - KeyBanc Capital analysts believe Amazon will benefit from the AI boom, with AWS continuing strong growth and potential revenue acceleration driven by data center clusters and clients like Anthropic, maintaining an overweight rating with a $300 price target [6] Broadcom Insights - Broadcom saw a price target increase from Goldman Sachs, now set at $435, up from $380, due to expected sustained strength in artificial intelligence [7] - Analysts project AI revenue for fiscal year 2026 to reach $45.4 billion, reflecting a year-over-year increase of approximately 128%, with potential growth to $77.3 billion in 2027, a 70% rise [8] - Raymond James resumed an outperform rating on Broadcom with a price target of $420, citing the company's position as a share gainer in the AI sector and anticipating continued upward estimate revisions [9][10] Oscar Health Upgrade - Oscar Health was upgraded to an overweight rating by Piper Sandler, with a new price target of $25, up from $13, due to expected market share and margin expansion following the expiration of enhanced premium tax credits at the end of the year [11]

Group 1 - President Trump's support for a two-year extension of expiring Affordable Care Act (ACA) health insurance subsidies has led to a rally in shares of Centene and Oscar Health [1][4] - Wall Street is optimistic that some form of subsidy extension will be approved, despite facing opposition from GOP [1] - The fate of the expiring ACA subsidies remains uncertain following a recent government funding deal [2] Group 2 - Trump's comments regarding diverting federal funds from "money-sucking" health insurers have positively impacted S&P 500 health care stocks [4] - Oscar Health has seen a significant increase in its Relative Strength (RS) rating, jumping to 87 [4] - The health care sector is betting that a deal regarding ACA subsidies will help prevent a government shutdown [4]